Maximizing Pharmaceutical Licensing Opportunities

Date: June 22, 2011
Pages: 153
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M1DA6E5A3F8EN
Leaflet:

Download PDF Leaflet

Maximizing Pharmaceutical Licensing Opportunities
Introduction

The report reviews the key trends in pharmaceutical licensing, examining deal volumes, values and structure. Therapeutic focus is also covered along with detailed profiles of the strategies of 10 leading pharmaceutical companies. The report also sets out future directions for licensing and alliance activity.

Features and benefits
  • Understand why licensing deals have become an integral part of Big Pharma strategies, along with the future impact of these strategies.
  • Identify the factors that are crucial to success in the licensing sphere, and the potential pitfalls that must be avoided.
  • Learn how leading players manage the licensing process, and pinpoint changes in their approach to licensing strategy.
  • Track recent changes in deal-making volumes, in-licensing/out-licensing ratios and the type of assets being targeted in major transactions.
  • Quantify financial commitments by licensees to external assets, and understand why the financial structure of licensing deals has begun to change.

Highlights

For an increasingly risk-averse industry, licensing deals represent a more affordable, less risky alternative to M&A transactions. They are being used to strengthen pipelines, manage major brand life-cycles, expand or restructure portfolios, access new technologies, and enter new geographical markets.

Cancer has emerged as the therapeutic area in which most deals are being struck. Other key therapy area targets include infectious disease, CNS disorders, metabolic/endocrine disease and auto-immune/inflammatory conditions. Rights to assets in these five therapy areas were traded in around two-thirds of all deals.

Declared financial commitments to assets licensed by the world’s ten biggest pharmaceutical companies totaled more than US$78bn in the five-year period to 2010. GSK was the biggest contributor to that figure, signing deals involving up-front fees and potential milestone payments that could exceed US$19bn.

Your key questions answered
  • Why do a growing number of Big Pharma CEOs favor licensing and alliance deals over M&A transactions?
  • How do leading multinationals structure their licensing activities, and how are approaches changing?
  • What factors lie behind the recent upturn in deal-making volumes, and will the increase be sustained?
  • Which therapy areas are the subject of most licensing deals?
  • Which companies top the Big Pharma licensing league in terms of deal volumes and financial commitments?
EXECUTIVE SUMMARY

Pharmaceutical licensing
Pharmaceutical licensing trends
Big Pharma licensing profiles
Future trends in pharma licensing

ABOUT THE AUTHOR

Disclaimer

PHARMACEUTICAL LICENSING

Summary
Introduction
Mega-trends behind the pharma licensing boom
  An industry in flux
  Looking out, not in
Licensing
  Licensing versus M&A
  Goals and targets
  Procedures and approaches

PHARMACEUTICAL LICENSING TRENDS

Summary
Introduction
Deal volumes
The deal-making community
Licensing targets
Deal values
  Up-front payments
  Milestone payments

BIG PHARMA LICENSING PROFILES

Summary
Introduction
  Big Pharma deal-making volumes
  Financial commitments to in-licensed assets
  Leading therapy area targets
  Strategic deal making focus
  In-licensing strategies
Pfizer
  Licensing strategy
  Licensing activity
Novartis
  Licensing strategy
  Licensing activity
Sanofi
  Licensing strategy
  Licensing activity
Merck & Co.
  Licensing strategy
  Licensing activity
GlaxoSmithKline
  Licensing strategy
  Licensing activity
Roche
  Licensing strategy
  Licensing activity
AstraZeneca
  Licensing strategy
  Licensing activity
Johnson & Johnson
  Licensing strategy
  Licensing activity
Eli Lilly
  Licensing strategy
  Licensing activity
Abbott
  Licensing strategy
  Licensing activity

FUTURE TRENDS IN PHARMA LICENSING

Summary
Introduction
  Filling Big Pharma pipelines
  Accessing novel technologies
  Choice of licensing partners
  Hedging risks associated with pharmaceutical R&D
  Increasing patient focus
  Portfolio restructuring
  Beyond pharmaceutical licensing

APPENDIX

Scope
Methodology
Skip to top


Ask Your Question

Maximizing Pharmaceutical Licensing Opportunities
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: